Previous close | 13.48 |
Open | 13.92 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 13.92 - 13.92 |
52-week range | 10.00 - 16.50 |
Volume | |
Avg. volume | 714 |
Market cap | 9.462B |
Beta (5Y monthly) | 0.25 |
PE ratio (TTM) | 46.40 |
EPS (TTM) | 0.30 |
Earnings date | 16 July 2024 |
Forward dividend & yield | 0.50 (3.59%) |
Ex-dividend date | 21 Sept 2023 |
1y target est | N/A |
Swedish Orphan Biovitrum AB (publ) (Sobi®) has successfully completed the inaugural issue of senior unsecured bonds of SEK 3 billion under its newly established MTN programme.
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024